TCT 2015: Abbott's Absorb On Par With Metal DES But Longer Data Still Needed

Results of the ABSORB III trial, the US pivotal study of Abbott’s Absorb bioresorbable stent, met its primary non-inferiority endpoint, but the ABSORB III investigators concede much longer follow-up in more patients must be collected to know if Absorb improves patient outcomes compared to metal drug-eluting stents (DES).